Table 2 Awaiting FDA approval
From: Potential new targets for drug development in severe asthma
| Mechanism of Action | Biomarker | Outcomes | Significant Adverse Events | References | |
|---|---|---|---|---|---|
| Dupilumab (Completed phase III, under FDA review) | Anti-IL4R |
↑Peripheral eosinophils (≥300/uL) ↑Sputum eosinophils (≥3%) |
Decreased exacerbations and symptoms Improved FEV1 Decreased glucocorticoid use Decreased FeNO |